SKSiddharth Karanth

Siddharth Karanth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Siddharth Karanth has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis

    by Tendai Mugwagwa, Benjamin A. Abramoff, Siddharth Karanth, Tram Nham, Ravi K. Goyal, Elizabeth Esterberg, Gurinder S. Sidhu, Alon Yehoshua, Ruth Mokgokong

    Coronavirus Disease 2019 (COVID-19) placed a significant burden on healthcare systems that persisted beyond the first waves of the pandemic1–6. Patients at high risk of severe COVID-19, including o...

  • Open Access

    Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma

    by Jeffrey Weber, Waqas Haque, Svetomir N Markovic, April K S Salama, Inderjit Mehmi, Ryan J Sullivan, Yana G Najjar, Alexander C J van Akkooi, Alexander M Menzies, Georgina V Long, et al.

    Background: In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat resection following relapse on/after 1L adjuvant CPI. Patients and methods: This was a retrospective review of BRAF V600-mutated resected stage III/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant CPI immunotherapy, relapsed locoregionally/distantly, were again resected to no evidence of disease, and received dabrafenib/trametinib (dab/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS) from initiation of 2L adjuvant dab/tram (RFS-2), analyzed via Kaplan-Meier methods. Results: Thirty-eight patients were included (median age 50 years, 63% male, 87% stage III, median follow-up 19 months from 2L dab/tram initiation). Median dab/tram duration was 10.1 months (range: 1 day–22.7 months), with half discontinuing due to progression or adverse events. Median (95% CI) RFS-2 was 18.9 (14.9–28.1) months, with 91%, 81%, and 58% remaining relapse-free at 6, 12, and 18 months, respectively. Most patients remained distant metastasis-free at 6, 12, and 18 months (97%, 85%, and 71%, respectively). Two patients were deceased at the last follow-up, with 97% alive at 18 months. Conclusions: Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab/tram initiation, with only 2 deaths observed. Dab/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.


  • Open Access

    Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer

    by Adam Brufsky, Marilyn L. Kwan, Rickard Sandin, Stella Stergiopoulos, Siddharth Karanth, Ashley S. Cha-Silva, Doris Makari, Ravi K. Goyal

    Purpose Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC) in clinical trials and real-world studies. However, investigations of survival gains in broader HR+/HER2− mBC populations using epidemiological approaches are limited. Methods This retrospective study used SEER registry data to assess breast cancer-specific survival (BCSS) in patients diagnosed with HR+/HER2− de novo mBC from 2010 to 2019. Kaplan–Meier and Cox proportional hazards models were used to compare BCSS in patients diagnosed before (2010‒2013 with follow-up to 2014) and after (2015‒2018 with follow-up to 2019) the 2015 guideline recommendations for CDK4/6i use. A comparison was made to patients with HR+/HER2-positive (HER2+) de novo mBC, for which no major guideline changes occurred during 2015–2018. Results Data from 11,467 women with HR+/HER2− mBC and 3260 women with HR+/HER2+ mBC were included. After baseline characteristic adjustment, patients with HR+/HER2− mBC diagnosed post-2015 (n = 6163), had an approximately 10% reduction in risk of BC-specific death compared with patients diagnosed pre-2015 (n = 5304; HR = 0.895, p < 0.0001). Conversely, no significant change was observed in HR+/HER2+ BCSS post-2015 (n = 1798) versus pre-2015 (n = 1462). Similar results were found in patients aged ≥ 65 years. Conclusion Using one of the largest US population-based longitudinal cancer databases, significant improvements in BCSS were noted in patients with HR+/HER2− mBC post-2015 versus pre-2015, potentially due to the introduction of CDK4/6i post-2015. No significant improvement in BCSS was observed in patients with HR+/HER2+ mBC post-2015 versus pre-2015, likely due to the availability of HER2-directed therapies in both time periods.


  • Open Access

    Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study

    by Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Julien Rombi, Keith L Davis, Nydia Caro, Teddy Saliba

    Aim: To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14). Methods: In an oncologists-led retro... Plain language summary – Real-world study that investigated the outcomes of different therapies used to treat non-small-cell lung cancer patients with mesenchymal-epithelial transition exon 14 skip... Tweetable abstract This real-world study of clinical outcomes showed capmatinib to be effective in first-line treatment of patients with advanced/metastatic NSCLC with MET exon 14 skipping mutation.


  • Open Access

    Surge in Incidence and Coronavirus Disease 2019 Hospital Risk of Death, United States, September 2020 to March 2021

    by Bela Patel, Robert E Murphy, Siddharth Karanth, Salsawit Shiffaraw, Richard M Peters, Samuel F Hohmann, Raymond S Greenberg

    Background: Studies of the early months of the coronavirus disease 2019 (COVID-19) pandemic indicate that patient outcomes may be adversely affected by surges. However, the impact on in-hospital mortality during the largest surge to date, September 2020–March 2021, has not been studied. This study aimed to determine whether in-hospital mortality was impacted by the community surge of COVID-19. Methods: This is a retrospective cohort study of 416 962 adult COVID-19 patients admitted immediately before or during the surge at 229 US academic and 432 community hospitals in the Vizient Clinical Database. The odds ratios (ORs) of death among hospitalized patients during each phase of the surge was compared with the corresponding odds before the surge and adjusted for demographic, comorbidity, hospital characteristic, length of stay, and complication variables. Results: The unadjusted proportion of deaths among discharged patients was 9% in both the presurge and rising surge stages but rose to 12% during both the peak and declining surge intervals. With the presurge phase defined as the referent, the risk-adjusted ORs (aORs) for the surge periods were rising, 1.14 (1.10–1.19), peak 1.37 (1.32–1.43), and declining, 1.30 (1.25–1.35). The surge rise in-hospital mortality was present in 7 of 9 geographic divisions and greater for community hospitals than for academic centers. Conclusions: These data support public policies aimed at containing pandemic surges and supporting healthcare delivery during surges.


  • Predictive factors for success of awake proning in hypoxemic respiratory failure secondary to COVID-19: A retrospective cohort study

    by Sujith V. Cherian, Chang Li, Brad Roche, Stephan A. Reyes, Siddharth Karanth, Aditya P. Lal, Gabriel M. Aisenberg, Rosa M. Estrada-Y- Martin


  • Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis

    by Diego Adrianzen Herrera, Kith Pradhan, Rose Snyder, Siddharth Karanth, Murali Janakiram, Ioannis Mantzaris, Ira Braunschweig, Anjali Budhathoki, Urvi A. Shah, Amit K. Verma, et al.


  • Clinical Characteristics and Etiologies of Miliary Nodules in the US: A Single-Center Study

    by Moiz Salahuddin, Siddharth Karanth, Daniel Ocazionez, Rosa M Estrada-Y-Martin, Sujith V. Cherian


  • Factors Affecting Racial Disparities in End-of-Life Care Costs Among Lung Cancer Patients

    by Siddharth MBBS Karanth, Suja S. Mha Rajan, Frances L. Revere, Gulshan Sharma

    Objectives: Racial disparities exist in end-of-life lung cancer care, which could potentially lead to considerable racial differences in end-of-life care costs. This study for the first time estimates the racial differences in end-of-life care costs among lung cancer patients, and identifies and quantifies factors that contribute the most to these differences using a statistical decomposition method. Methods: This is a retrospective analysis of patients 66 years and older, diagnosed with stage I-IV lung cancer, who died on or before December 31, 2013, using the Surveillance Epidemiology and End Result-Medicare data from 1991 to 2013. Ordinary least square regression of logarithmically transformed cost was used to estimate racial differences in end-of-life care costs among lung cancer patients. Blinder-Oaxaca decomposition was used to identify and quantify factors that contributed the most to these differences. Results: Non-Hispanic blacks had 10% to 13% higher end-of-life care costs as compared with non-Hispanic whites. Geographic variations, baseline comorbidity indices and stage at diagnosis contributed the most to explaining the racial differences in costs, with geographic variation explaining most of the differences. However, the observed factors could only explain 25% to 32% of the racial differences in end-of-life care costs. Conclusions: Geographic differences in access to timely and appropriate care, and provider practice patterns, should be examined to understand the reasons behind geographic variations in racial disparity. Provider-level educational interventions to reduce small area practice variations and differential management of patients by race, as well as racially sensitive patient-level educational and navigational interventions might be critical in improving quality of care and reducing costs during end-of-life.